CHICAGO, Nov. 9, 2012 /PRNewswire/ -- The Female Health
Company (NASDAQ-CM: FHCO), which manufactures and markets the
FC2 Female Condom® (FC2), today announced
that Donna Felch will retire from
her position as Vice President and Chief Financial Officer
effective December 31,
2012. The Company also announced that Ms. Felch was
appointed to the Company's Board of Directors on November 7, 2012. Following her retirement,
she will continue her affiliation with the Company as a
Consultant.
(Logo:
http://photos.prnewswire.com/prnh/20120712/MM39764LOGO)
In connection with Ms. Felch's retirement, the Company announced
that Michele Greco will become Vice
President and Chief Financial Officer effective January 1,
2013. Ms. Greco's employment with the Company commenced
on November 9, 2012
O.B. Parrish, the Company's
Chairman and Chief Executive Officer, noted, "I have enjoyed
working with Donna tremendously during her six year tenure as a key
member of our executive management team. On behalf of
management and the Board of Directors, I would like to express our
sincere appreciation for her contributions to The Female Health
Company's success, and we are particularly pleased that she will
continue her affiliation with the Company as a Consultant and
Director."
"We are delighted to welcome Michele
Greco as our new Vice President and Chief Financial
Officer," continued Parrish. "Her career with one of the
world's largest public accounting firms, where she successfully
executed many international assignments, is ideally suited to The
Female Health Company's global growth initiatives. I look
forward to working with her, and we expect a smooth transition in
this key management position over the next several
weeks."
Ms. Greco is a DePaul University
graduate and a CPA. She has nearly 30 years of experience in
public accounting with Ernst & Young LLP, where she was named
partner in 1994 -- a position she held until March 2009. In
addition to her responsibilities as audit partner, Ms. Greco
advised on a broad range of financial transactions during her
tenure at Ernst & Young, including IPO's, mergers and
acquisitions, and debt and equity transactions. She counseled
large and small clients in a variety of industries in the U.S., the
U.K., Germany, Japan, France
and the Netherlands. From
January 2011 to February 2012, Ms. Greco provided consulting
services to Systems Research Incorporated as a recruiter of finance
professionals. From March 2009 to January 2011, she
was involved in a series of personal business ventures.
About The Female Health Company
The Female Health Company, based in Chicago, Illinois, manufactures and markets
the FC2 Female Condom® (FC2), which is available in the U.S.
and approximately 138 other countries globally. The Company
owns certain worldwide rights to the FC2 Female Condom®,
including patents that have been issued in the U.S., the European
Union, Canada, Australia, South
Africa, Japan, The People's Republic of China, Spain, Mexico, Greece, Turkey and the African Regional Intellectual
Property Organization (ARIPO), which includes Botswana, The Gambia, Ghana, Kenya,
Lesotho, Malawi, Mozambique, Namibia, Sierra
Leone, Somalia,
Sudan, Swaziland, Uganda, United Republic of Tanzania, Zambia and Zimbabwe. FC2 patent
applications are pending in various countries. The FC2
Female Condom® is the only available FDA-approved product
controlled by a woman that offers dual protection against sexually
transmitted diseases, including HIV/AIDS, and unintended
pregnancy. The World Health Organization (WHO) has cleared
FC2 for purchase by U.N. agencies.
"Safe Harbor" statement under the Private Securities
Litigation Reform Act of 1995:
The statements in this release which are not historical facts
are forward-looking statements based upon the Company's current
plans and strategies, and reflect the Company's current assessment
of the risks and uncertainties related to its business, including
such things as product demand and market acceptance; the economic
and business environment and the impact of government pressures;
currency risks; capacity; efficiency and supply constraints; and
other risks detailed in the Company's press releases, shareholder
communications and Securities and Exchange Commission
filings. Actual events affecting the Company and the impact
of such events on the Company's operations may vary from this
currently anticipated.
For more information about the Female Health Company visit the
Company's website at http://www.femalehealth.com and
http://www.femalecondom.org . If you would like to be
added to the Company's e-mail alert list, please send an e-mail to
FHCInvestor@femalehealthcompany.com .
SOURCE The Female Health Company